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Background: To investigate the feasibility and safety of transthoracic HIFU ablation for
blocking cardiac electrical conduction in a canine model.
Methods: Degreasing, degassing and establishment of artificial pleural effusion were
induced in 21 canines. We used HIFU to target the right side of the central fibrous body
guided by echocardiography. 10 canines received ablation only, 8 canines received
ablation and cardiac pacing for 2h, while 3 canines received ablation and cardiac pacing
for 3 months. At each endpoint, the targeted tissues were retrieved for gross, histological
and immunohistochemical evaluation.
Results: Complete atrioventricular block (AVB) was achieved in all 21 canines using
400W22.58.8s HIFU energy after acoustic coupling was improved. Recovery of AV
conduction was observed neither in the 8 canines with cardiac pacing for 2h, nor in the 3
canines which were maintained with cardiac pacing for 3 months. The ablation lesion had
a clear margin at the top part of interventricular septum with a necrosis of the conduction
fiber in all analyzed animals whereas small fibrosis of the target regions within intact
endothelium was found in the animals maintained for 3 months. No other complications
were observed except that mild hemorrhagic injury in the inferior lobe of left lung was
found in one animal.
Conclusions: Our findings indicate that the transthoracic HIFU for blocking cardiac
conduction is specific, safe and efficient, lending itself as a potentially novel approach for
arrhythmia therapy.
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Background: Patients with severe tricuspid regurgitation (TR) represent a therapeutic
challenge. Combining the excellent (pre-)clinical experience with decellularized heart
valves and the transcatheter valve implantation results, we sought to evaluated the
functional and structural outcome of decelluarised pericardial tissue valves(dTV) in the
venous circulation using a chronic animal model of TR.
Methods: 8 decellularized pericardial tissue valves were implanted in the inferior(IVC)
and superior(SVC) vena cava in a sheep model of severe TR. The devices were assembled
using self-expanding nitinol stents and bovine pericardia decellularized by an established
protocol (n8). Glutaraldehyde-fixed(GA) tissue served as control(GA-TV, n8). Prior
to implantation, severe TR was created by pulmonary banding and papillary muscle
avulsion. Valve implantation was performed by means of a 21F-catheter. After 6 month,
valve function and structural maturation were analysed by echocardiography, histology,
immunohistology and electron microscopy.
Results: Device was successful in all animals. After valve implantation, cardiac output
increased significantly from 4.4 l/min to 5.1 l/min (p0.05) and competent valve function
was verified by angiography. At 6 month, angiographic and echocardiographic evaluation
revealed moderate to severe regurgitation in all nTV. In contrast, 5 out of 8 dTV showed
excellent function with only minor regurgitation. In these animals autopsy revealed
preserved structural integrity of the valve with tender leaflets without signs of thrombosis
or calcification. In contrast, nTV leaflets showed severe valve degeneration with large
calcification areas. Microscopic and histologic analysis confirmed endothelial repopula-
tion of the leaflets in both valve types. However, in dTV additional interstitial reseeding
was noted.
Conclusions: In the venous low-pressure circulation, decellularized tissue valves show
superior functional performance compared to native pericardial tissue valves. Macro-
scopic and microscopic analysis suggests preserved structural integrity and advanced
endothelial and interstitial repopulation without evidence of degradation in decellularized
tissue valves.
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Transcatheter Device Closure Of Atrial Septal Defect In Infants And Young
Children
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Background: Transcatheter closure of atrial septal defect (ASD) is the procedure of
choice for central fossa-ovalis defects. There is limited information on safety and
follow-up of transcatheter closure of ASD in young children. To describe our institutional
experience on transcatheter closure of atrial septal defect in infants and children weighing
10 kg.
Methods: Records of 56 patients weighing 10 kg (mean age: 28.70  9.54 months,
range 4 - 50 months; mean weight: 8.98  1.29 kg, range 4 - 10 Kg) who underwent
transcatheter closure of ASD in our Institute (January 2007- December 2011) were
reviewed.
Results: The study population represented 8.6 % of our total experience in this period.
Indications for closure included failure to thrive (75.1%), recurrent respiratory infections
(39.4%) and or heart failure (7.2 %). Case selection was through trans-thoracic
echocardiography. The ASD size was 14.66  3.27mm (range 9-23 mm) and mean
pulmonary artery pressure was 27  6.42 mm of Hg. Closure was achieved in all with
mean fluoroscopy time of 8.61  6.75 minutes; device size ranged from 9 to 24 mm.
General anesthesia and transesophageal echo guidance was utilized in 22 (39.3%). One
patient had embolisation of device immediately after release and was surgically retrieved.
Transient ECG abnormalities included first degree AV block (2) and junctional rhythm
(3). All had normal sinus rhythm at 24 hrs after procedure. On follow up (median 6
months; range 1-53 months) all were symptom free with over all improved weight z
scores (from -2.00  0.0 to -1.81  0.29; p  0.008), normal ECGs and satisfactory
device positions on echocardiograms.
Conclusions: The immediate and short-term follow up results of transcatheter device
closure of ASD are encouraging and suggest that the indications can be broadened to
include selected children  10 Kg.
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Long-term results of a comparison of three patent foramen ovale closure
devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex
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Background: Percutaneous patent foramen ovale (PFO)-closure for secondary stroke
prevention is discussed controversially, and long-term data comparing different closure
devices are very limited.
Methods: This is a prospective trial comparing procedural complications and long-term
results after PFO closure in 660 patients with cryptogenic stroke randomized to three
different closure devices: Amlpatzer (AGA Medical, Golden Valley, Minnesota), Helex
(W.L. Gore and Associates, Flagstaff, Arizona) and CardioSEAL-STARflex (NMT
Medical, Boston, Massachusetts), 220 patients per group). Patients were monitored for
recurrent cerebral ischemia (stroke, TIA or Amaurosis fugax), death and rate of complete
PFO closure during 5 year follow-up (including periprocedural events).
Results: We examined 660 patients (361 men, 299 women, mean age 49.3	/1.9
years). All PFO closures were successful technically. The procedure was complicated by
pericardial tamponade requiring surgery in 1 patient (Amplatzer device) and device
embolization in 3 patients (all Helex devices).
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5 year results
Amplatzer
(n220)
Helex
(n220)
CardioSEAL-
STARflex
(n220) p-value
total
(n660)
Acute Complications
Pericardial tamponade 1 (0.5%) 0 0 0.37 1(0.2%)
Device embolization 0 3 (1.4%) 0 0.049# 3 (4.5%)
Long-term Complications
Thrombus formation 0 1 (0.5%) 11 (5%) 0.0001* 12 (1.8%)
Atrial fibrillation 8 (3.6%) 5 (2.3%) 27 (12.3%) 0.0001* 40 (6%)
Peripheral embolism 0 0 0 1 0
Non-neurological death 3 (1.4%) 4 (1.8%) 3 (1.4%) 0.90 10 (1.5%)
Recurrent Neurological Events
TIA 0 4 (1.8%) 6 (2.7%) 0.058* 10 (1.5%)
Stroke 2 (0.9%) 4 (1.8%) 6 (2.7%) 0.36 12 (1.8%)
Cerebral Death 1 (0.5%) 1 (0.5%) 1 (0.5%) 1 3 (0.5%)
Complete PFO-closure 220
(100%)
213 (96.8%) 219 (99.5%) 0.004# 652
(98.8%)
*this represents the p-value comparing the CardioCEAL-STARflex device to both, the
Amplatzer and the Helex device. There was no significant difference between the
Amplatzer and Helex device.
#this represents the p-value comparing the Helex device to both, the Amplatzer and the
CardioSEAL-STARflex device. There was no significant difference between the Amplatzer
and CardioSEAL-STARflex device.
Conclusions: The periprocedural and long-term neurological event rates are low
regardless of the device used. The recurrent neurological event rate was significantly
higher after CardioSEAL-STARflex than after Amplatzer or Helex implantation. This has
important implications regarding the interpretation of trials comparing PFO closure to
medical management.
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Role Of Non-ECG Gated Contrast CT In Preventing Percutaneous Pulmonary
Valve Implantation-Related Coronary Compromise
Paul Dunne1, Oliver Monfredi2, Bernard Clarke1, Gerard Murphy1,
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Background: Percutaneous pulmonary valve implantation (PPVI) is a non-surgical
transcatheter treatment for right ventricular to pulmonary artery conduit dysfunction. One
of the rare but significant risks of this procedure is acute coronary occlusion following
valve deployment. Proximity of coronary arteries has previously been assessed using
time-consuming and costly ECG gated contrast CT scanning or MRI. We assessed the
utility of non-ECG gated contrast CT scanning as an alternative for assessing the coronary
position in patients planned to undergo PPVI.
Methods: We studied a series of 22 consecutive patients presenting to our institution for
PPVI. The underlying diagnoses of these patients varied. In all of the patients, we used the
rapid, highly-accessible and relatively cheap technique of non-ECG gated 32-slice
contrast CT to assess the relationship of the coronary arteries to the proposed site of PPVI
in 3 planes – axial, saggital and coronal. Patients were only subsequently selected for
PPVI if there was a distance of at least 3 mm between the main coronary vessels and
region of proposed valve deployment.
Results: The mean age of patients selected for PPVI was 26. Non-ECG gated contrast CT
scanning was found to be highly effective in detecting the position of the coronary arteries,
allowing coronary identification in the axial plane 93% of the time, saggital plane 87% of
the time and in the coronal plane 87% of the time. No patient experienced acute coronary
occlusion when the exclusion criteria of3 mm between proposed valve deployment site
and nearest distance of coronary artery was employed.
Conclusions: Non-ECG gated contrast CT is effective, rapid and cost-effective in
allowing coronary characterisation before PPVI. A distance of 3 mm between coronary
artery and valve implantation site seems to be a safe distance to avoid PPVI related
coronary occlusion. More studies are required to assess this in further detail.
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Transcatheter closure of perimembranous ventricular septal defect with the
Amplatzer® Membranous VSD Occluder 2
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Background: Transcatheter closure of peri-membranous ventricular septal defects
(pmVSDs) has been associated with a significant risk of complete heart block, leading
most groups to abandon the technique. Our objective was to describe the initial world
experience of pmVSD closure with a newly designed occluder.
Methods: Patients with pmVSD underwent catheter closure using the Amplatzer®
Membranous VSD Occluder 2 (AGA – St Jude, Minneapolis, MN, USA).
Results: Nineteen patients from the 4 centers initially involved worldwide were
prospectively included and followed for at least 30 days (median 48, range 31 – 245 days).
Patients ranged in age from 1.4 to 62 years (median 6 years) and in weight from 9.3 to 96
kg (median 26 kg). The Qp/Qs ratio was (mean  SD) 1.9  1.6. The size of the defect
on left ventricular side was 9.9  3.5 mm (range 4.6 – 16 mm) and the orifice on right
ventricular side was 8.1 2.8 mm (range 3.9 – 14 mm) by echocardiography. Mean device
size was 9.4 2.4 mm (range 5 – 14 mm). An eccentric device was used in 9 patients (47%)
and a concentric device in 10 (53%). A device was successfully implanted in 18 patients
(95%). Procedural time was 122  39 min (range 60 – 207 min). There were no significant
procedural complications. Mild (0-2 mm) residual shunt was initially observed in 14 patients
(78%). At last follow-up, mild residual shunt was still observed in only 3 patients (17%). There
was no significant increase of aortic or tricuspid regurgitation. No patient showed any degree
of AV block, although one patient developed a left anterior fascicular block. Holter evaluation
was obtained in 13/18 patients, and was normal in all.
Conclusions: Transcatheter closure of pmVSD with the Amplatzer® pmVSD Occluder
2 is safe and effective. No conduction abnormalities or any other complications were
observed on short-term follow of this initial human series.
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Ventricular Septal Defects Using the Amplatzer Asymmetric Perimembranous
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Background: In this report we present 10 year experience with 78 patients (pts) with
perimembranous ventricular septal defects (PMVSDs) who underwent transcatheter
closure at 5 different Institutions with the Amplatzer asymmetric PMVSD occluder.
Methods: The age of the pts ranged from 0.3 to 15 years. During the study period 35
other patients were excluded from transcatheter closure because they did not fulfil the
patient selection criteria (distance less than 2 mm from the PMVSD to the aortic valve,
size of VSD in relation to patients age).
Results: The devise was permanently implanted in 72/78 patients. Complete occlusion of
the communication at six month, one-year, and 2-year follow-up was observed in 93%, 97
%, and 97% patients, respectively. Main complications included: Early. Were observed in
patients less than one year (body weight  8 Kg) and included: a. Device embolization
(2 patients-catheter and surgical removal, respectively), b. severe procedural bradycardia
(5 pts) and c. Mobitz II and complete heart block heart in 3 and 1 patients respectively.
(sinus rhythm after device removal). Late (follow-up 6 months-10 years). Complete heart
block was developed in one patient 4-year old with Down syndrome. No other patient
developed heart block during the follow-up. Three patients developed mild aortic
regurgitation. In one of them the regurgitation was not seen at the 1-year follow-up. No
other complications were observed.
Conclusions: Transcatheter closure using the Amplatzer APMVSD occluder is as a safe
and effective nonsurgical alternative that should be offered in properly selected patients
with PMVSDs. It should be noted, however, that with the current design of the
occluder-delivery system the procedure carries an increased risk in small patients less than
one-year of age. Finally, due to anatomic reasons, this therapy cannot be offered to
significant number of patients with these defects.
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Novel System for Detection of Cardiac Right to Left Shunts
Robert Sommer1, Russell Brandwein2, David Dobson3, Eric Eggers3,
Andrew Eggers3
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Background: The current “gold standard” for detection and quantification of right-to-left
shunts (RLS) is transesophageal echocardiography (TEE). The Flow Detection System (FDS)
(Cardiox Corp., Columbus, OH) is a new, minimally invasive, diagnostic test, based on
transdermal detection of Indocyanine Green (ICG) dye (Pulsion Medical Systems AG,
Munich, Germany). The present study was performed to determine optimum ICG dosing and
injection timing protocols, as well as the system’s accuracy in the detection of RLS.
Methods: Various ICG dosages and injection timing protocols were evaluated in eight
(8) patients, with known RLS, to determine the optimal dose and injection timing to
facilitate detection of RLS with FDS. 20 additional patients underwent testing with power
m-mode transcranial Doppler (TCD) and subsequent FDS. Ten (10) patients with large
RLS, (Spencer grades IV or V by TCD) were selected to comprise the study group. Ten
(10) additional patients with Spencer grades 0 or I shunt by TCD were selected to
comprise a control group. All patients were evaluated just prior to a scheduled
catheterization, with both TCD and FDS using the dosing and timing parameters
developed in the initial cohort of eight patients. In the study group, results were also
compared with RLS assessment by intra-cardiac echocardiography (ICE - Johnson &
Johnson, NJ) performed during the catheterization.
Results: All ten study subjects with TCD-proven RLS exhibited a Shunt Conductance
Index (SCI) 0, reflecting the presence of a RLS (sensitivity 100%). FDS was also in
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